Reported results
- Total revenue from continuing operations for the third quarter of 2026 was $1.8 million, as compared to $1.1 million for the third quarter of 2025.
- Net income from continuing operations for the third quarter of 2026 was $0.2 million, or $0.04 net income per basic and diluted share, compared to a net loss of $13.1 million, or $3.25 net loss per basic and diluted share, for the third quarter of 2025.
- Loss from operations for the third quarter of 2026 was $12,865 thousand, compared to $5,411 thousand for the third quarter of 2025.
- Research and development expenses were $8,266 thousand for the three months ended September 30, 2026, compared to $1,209 thousand for the three months ended September 30, 2025.
- As of September 30, 2026, Kyntra Bio reported $44.1 million in cash, cash equivalents, investments, and accounts receivable.
Guidance
- The company expects to save over $20 million in operating expenses in 2027 and 2028 from the termination of the FG-3246 study.
- The company expects its cash, cash equivalents, investments, and accounts receivable to be sufficient to fund operating plans into 2028.
- Initiation of the pivotal Phase 3 trial of roxadustat for the treatment of anemia in LR-MDS patients with high transfusion burden is planned in the first quarter of 2027, subject to the execution of either a strategic partnership or an external capital raise.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.
